Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Mayne Pharma Group Ltd (MYX) Shares Jump On Efudex Deal

Mayne Pharma Group Limited (ASX:MYX) said it will buy Efudex® from Spear Pharmaceuticals Inc for up to $US30 million.

In an announcement this morning Australian pharmaceuticals business Mayne Pharma Group Ltd (ASX: MYX) said it will buy Efudex® from Spear Pharmaceuticals Inc for up to $US30 million.

Mayne Pharma is a speciality pharmaceutical company, manufacturing and selling generics and branded drugs throughout Australia and the world.

Efudex® is also known as Fluorouracil and is used to treat skin cancer and other skin disorders.

Mayne Pharma CEO Scott Richards said the deal will complement the company’s existing product suite and build on its growth plans.

“Fluorouracil cream will further diversify earnings and strengthen Mayne Pharma’s position in the US dermatology market,” Richards added.

The deal values Efudex® up to $US30 million. Mayne Pharma will pay Spear Pharmaceuticals $US20 million upfront, including $US4 million of Mayne Pharma shares. Mayne could also pay an additional $US10 million to Spear, depending on competition in the market over the next three years.

Quoting data from IQVIA from May 2018, Mayne Pharma said generic sales of Efudex® total $US66 million and volumes have been growing around 10% per year over the past five years.

The acquisition is expected to be immediately earnings per share (EPS) accretive, Richards said.

“Mayne Pharma is committed to pursuing accretive transactions, such as this one, to deliver further value to its shareholders, particularly where we can leverage our existing commercial operations and know-how,” Richards concluded.

Mayne Pharma shares were trading 3% higher on Monday, according to Google Finance.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

5%+ in passive income

Owen Rask’s investing report available

With bond ETFs like ASX:IAF and the S&P 500 riding high, now could be one of the best times to start earning passive income from a portfolio of shares and ETFs.

In this free analyst report, our Chief Investment Officer, Owen Rask, names 10 ASX stocks and ETFs to watch.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Skip to content